When a post-menarchal adolescent presents to a health professional with bacterial vaginosis symptoms, a careful evaluation for sexually transmitted diseases and other risk factors for bacterial vaginosis should be considered. There are no adequate and well-controlled studies of CLEOCIN Vaginal Ovules in pregnant women during the first trimester of pregnancy. If you notice other effects not listed above, contact your doctor or pharmacist.Call your doctor for medical advice about side effects.

(See The following adverse reactions and altered laboratory tests have been reported with the There have been reports of pseudomembranous colitis following the administration of clindamycin vaginal cream.Vaginally applied clindamycin phosphate contained in CLEOCIN Vaginal Ovules could be absorbed in sufficient amounts to produce systemic effects. Properly discard this product when it is expired or no longer needed. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of CLEOCIN Vaginal Ovules, because approximately 30% of the clindamycin dose is systemically absorbed from the vagina.Onset of pseudomembranous colitis symptoms may occur during or after antimicrobial treatment.The patient should also be advised that these suppositories use an oleaginous base that may weaken latex or rubber products such as condoms or vaginal contraceptive diaphragms. Do not double the dose to catch up.Store at room temperature away from light and moisture.

Cross resistance has been demonstrated between lincosamides, macrolides and streptogramins B in some organisms. If someone has overdosed and has serious symptoms such as passing out or This medication has been prescribed for your current condition only. Topical (topical solution, gel, and lotion) and vaginal (cream, ovules) preparations of clindamycin are contraindicated in patients with a history of regional enteritis or ulcerative colitis, or a history of pseudomembranous colitis; other product preparations warn against use in patients with pseudomembranous colitis. There are no adequate and well-controlled studies of CLEOCIN Vaginal Ovules in pregnant women.Other pathogens commonly associated with vulvovaginitis, e.g., CLEOCIN Vaginal Ovules are contraindicated in individuals with a history of hypersensitivity to clindamycin, lincomycin, or any of the components of this vaginal suppository. Monitor the breast-fed infant for possible adverse effects on the gastrointestinal flora, such as diarrhea, candidiasis (thrush, diaper rash) or rarely, blood in the stool indicating possible antibiotic-associated colitis.The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for clindamycin and any potential adverse effects on the breast-fed child from clindamycin or from the underlying maternal condition.The safety and efficacy of CLEOCIN Vaginal Ovules in the treatment of bacterial vaginosis in post-menarchal females have been established on the extrapolation of clinical trial data from adult women. CLEOCIN Vaginal Ovules should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Moniliasis, as reported here, includes the terms: vaginal or nonvaginal moniliasis and fungal infection. Do not use it later for another infection unless your doctor tells you to.If you miss a dose, use it as soon as you remember. If it is near the time of the next dose, skip the missed dose. In addition, the recommended daily and total doses of intravaginal clindamycin suppository are far lower than those typically administered in oral or parenteral clindamycin therapy (100 mg of clindamycin per day for 3 days equivalent to about 30 mg absorbed per day from the ovule relative to 600 to 2700 mg/day for up to 10 days or more, orally or parenterally).

Therefore, the use of such products within 72 hours following treatment with CLEOCIN Vaginal Ovules is not recommended. Fertility studies in rats treated orally with up to 300 mg/kg/day (31 times the human exposure based on mg/mIn clinical trials with pregnant women, the systemic administration of clindamycin during the second and third trimesters, has not been associated with an increased frequency of congenital abnormalities.Clindamycin vaginal ovules should be used during the first trimester of pregnancy only if clearly needed and the benefits outweigh the risks.

The safety and efficacy of CLEOCIN Vaginal Ovules in pre-menarchal females have not been established.Clinical studies of CLEOCIN Vaginal Ovules did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.In clinical trials, 3 (0.5%) of 589 nonpregnant women who received treatment with CLEOCIN Vaginal Ovules discontinued therapy due to drug-related adverse events. Studies indicate that a toxin produced by After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. The chemical name for clindamycin phosphate is methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-CLEOCIN Vaginal Ovules are semisolid, white to off-white suppositories for intravaginal administration. Uses. CLEOCIN Vaginal Ovules are also contraindicated in individuals with a history of regional enteritis, ulcerative colitis, or a history of "antibiotic-associated" colitis.Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia.